GBA-Associated Parkinson's Disease movement disorder
Conditions
Interventions
LTI-291 capsules (API-in-capsule) dosed at 3mg, 10mg, 30mg or 60 mg and
matching capsules containing 15 mg of Avicel as placebo.
Sponsors
Lysosomal Therapeutics Incorperated.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent prior to any study-mandated procedure 2. Healthy male or female subjects of non-childbearing potential (defined as postmenopausal with amenorrhea for at least 12 months) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy, 50 to 75 years of age (inclusive) at screening. 3. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum weight of 50 kg at screening. 4. All males must practice effective contraception and abstain from sperm donation during the study and be willing and able to continue contraception and abstention from sperm donation for at least 90 days after their last dose of study treatment. 5. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions
Exclusion criteria
Exclusion criteria: 1.Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature), 12-lead electrocardiogram (ECG)). Minor deviations of laboratory values from the normal range may be accepted, if judged by the Investigator to have no clinical relevance. 2. Clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects. 3. Any contra-indication for undergoing a lumbar puncture procedure (e.g. anatomical variations or local skin infection). 4. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening. 5. Systolic blood pressure (SBP) greater than 150 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 95 or less than 50 mm Hg at screening or baseline. 6. Abnormal findings in the resting ECG at screening defined as: a. QTcF > 450 msec for males or > 470 msec for females; b. Notable resting bradycardia (HR 100 bpm); c. QRS > 120 msec: d. Personal or family history of congenital long QT syndrome or sudden death; e. ECG with QRS and/or T wave judged to be unfavorable for a consistently accurate QT measurement (e.g., neuromuscular artefact that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves); f. Evidence of atrial fibrillation, atrial flutter, complete branch block, Wolf-Parkinson-White Syndrome, or cardiac pacemaker. 7. Use of any medications (prescription or over-the-counter [OTC]) that is suspected to interfere or interact with the study medication, within 14 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions are paracetamol (up to 4 g/day) and ibuprofen (up to 1g/day). Other exceptions will only be made if the rationale is clearly documented by the investigator. No exceptions will be made for: a. Any known inducer or inhibitor of CYP3A4, CYP1A2 or CYP2D6; b. Any drug known to inhibit blood coagulation. 8. Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions will only be made if the rationale is clearly documented by the investigator. 9. Participation in an investigational drug or device study within 3 months prior to first dosing. 10. History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units alcohol per week, drug abuse, or regular user of sedatives, hypnotics, tranquillizers, or any other addictive agent. 11. Positive test for drugs of abuse at screening or pre-dose. 12. Use of tobacco or nicotine products within 14 days before the first dose administration. 13. Demonstrates an excess in xanthine consumption (more tha
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Safety and tolerability endpoints - Pharmacokinetic endpoints - Pharmacodynamic endpoints | — |
Secondary
| Measure | Time frame |
|---|---|
| - Wet biomarker measurements - Genotyping | — |
Countries
Netherlands
Outcome results
None listed